189 related articles for article (PubMed ID: 34390022)
1. When innovation outpaces regulations: The legal challenges for direct-to-patient supply of investigational medicinal products.
Malone M; Ferguson P; Rogers A; Mackenzie IS; Rorie DA; MacDonald TM
Br J Clin Pharmacol; 2022 Mar; 88(3):1115-1142. PubMed ID: 34390022
[TBL] [Abstract][Full Text] [Related]
2. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
3. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
4. Direct-to-participant investigational medicinal product supply in clinical trials in Europe: Exploring the experiences of sponsors, site staff and couriers.
de Jong AJ; Santa-Ana-Tellez Y; Zuidgeest MGP; Grupstra RJ; Jami F; de Boer A; Gardarsdottir H;
Br J Clin Pharmacol; 2023 Dec; 89(12):3512-3522. PubMed ID: 37438875
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union.
de Jong AJ; Santa-Ana-Tellez Y; van Thiel GJMW; Zuidgeest MGP; Siiskonen SJ; Mistry D; de Boer A; Gardarsdottir H;
Clin Pharmacol Ther; 2021 Jun; 109(6):1517-1527. PubMed ID: 33666223
[TBL] [Abstract][Full Text] [Related]
6. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
Pashkov V; Soloviov A; Olefir A
Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
[TBL] [Abstract][Full Text] [Related]
7. Public information on shortages in the EU/EEA: improvements made between 2018 and 2020.
Abed I; Garcia Burgos J; Knudsen Y
Eur J Hosp Pharm; 2024 Jun; 31(4):344-347. PubMed ID: 36754622
[TBL] [Abstract][Full Text] [Related]
8. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
Borysowski J; Górski A
Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
[TBL] [Abstract][Full Text] [Related]
9. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.
Gluud C; Kubiak C; Whitfield K; Byrne J; Huemer KH; Thirstrup S; Libersa C; Barraud B; Grählert X; Dreier G; Geismann S; Kuchinke W; Temesvari Z; Blasko G; Kardos G; O'Brien T; Cooney M; Gaynor S; Schieppati A; de Andres F; Sanz N; Kreis G; Asker-Hagelberg C; Johansson H; Bourne S; Asghar A; Husson JM; Demotes-Mainard J
Trials; 2012 Mar; 13():27. PubMed ID: 22452964
[TBL] [Abstract][Full Text] [Related]
10. [The national legislation accompanying the approval procedure for clinical trials of medicinal products for human use under Regulation (EU) No. 536/2014].
Frech M; Dexel F; Burgard M; Seibel Y
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):12-20. PubMed ID: 36525035
[TBL] [Abstract][Full Text] [Related]
11. Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.
Dri DA; Praticò G; Gaucci E; Marianecci C; Gramaglia D
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959722
[TBL] [Abstract][Full Text] [Related]
12. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
13. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
14. Record linkage of population-based cohort data from minors with national register data: a scoping review and comparative legal analysis of four European countries.
Doetsch JN; Dias V; Indredavik MS; Reittu J; Devold RK; Teixeira R; Kajantie E; Barros H
Open Res Eur; 2021; 1():58. PubMed ID: 37645179
[No Abstract] [Full Text] [Related]
15. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
16. Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials.
Doua YJ; Dominicus H; Mugwagwa J; Gombe SM; Nwokike J
Trials; 2019 Apr; 20(1):212. PubMed ID: 30975193
[TBL] [Abstract][Full Text] [Related]
17. Status of the GCP guidelines in Europe.
Geussenhainer S
Methods Find Exp Clin Pharmacol; 1993 May; 15(4):223-8. PubMed ID: 8361259
[TBL] [Abstract][Full Text] [Related]
18. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law].
Geisler I; Hofmann HP; Nickel L
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454
[TBL] [Abstract][Full Text] [Related]
19. [Clinical trials for medicinal products. New European and national legal rules].
Kreutz G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):524-9. PubMed ID: 15887061
[TBL] [Abstract][Full Text] [Related]
20. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
